Eli Lilly and RNAi therapeutics specialist OliX Pharmaceuticals have entered into a global licensing agreement to advance a ...
WashU Medicine-led trial evaluating investigational drug from Eli Lilly and Company aims to stop disease before symptoms ...
Explore the potential of monoclonal antibodies in Alzheimer’s treatment, including breakthroughs and challenges in this ...
Agreement supports the research and development of up to five novel therapeutic antibodies identified through ... Our collaboration with Lilly enables us to apply our novel approach to a hugely ...
A US university has launched a prevention trial examining the use of Eli Lilly’s investigational ... determine if the investigational monoclonal antibody remternetug can remove plaques of ...
“This collaboration with Lilly represents a significant milestone for AdvanCell, recognizing our company as one of the leaders in the Pb-212 targeted alpha therapy space,” said Andrew Adamovich, CEO ...
Monoclonal antibodies have emerged as a promising approach in the fight against Alzheimer's disease, offering hope for slowing its progression. T ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback